Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$87.9b

Regeneron Pharmaceuticals Valuation

Is REGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REGN ($824.48) is trading below our estimate of fair value ($2194.35)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGN?

Other financial metrics that can be useful for relative valuation.

REGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.2x
Enterprise Value/EBITDA15.9x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does REGN's PE Ratio compare to its peers?

The above table shows the PE ratio for REGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average46.8x
AMGN Amgen
40.9x19.8%US$173.0b
BIIB Biogen
15.7x13.6%US$25.4b
ABBV AbbVie
69.7x28.0%US$355.5b
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
REGN Regeneron Pharmaceuticals
19.1x8.1%US$87.9b

Price-To-Earnings vs Peers: REGN is good value based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (273.6x).


Price to Earnings Ratio vs Industry

How does REGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: REGN is expensive based on its Price-To-Earnings Ratio (19.1x) compared to the US Biotechs industry average (17.2x).


Price to Earnings Ratio vs Fair Ratio

What is REGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.1x
Fair PE Ratio30.2x

Price-To-Earnings vs Fair Ratio: REGN is good value based on its Price-To-Earnings Ratio (19.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$824.48
US$1,089.43
+32.1%
11.2%US$1,230.00US$800.00n/a25
Nov ’25US$843.60
US$1,095.43
+29.9%
11.1%US$1,230.00US$800.00n/a25
Oct ’25US$1,046.91
US$1,157.67
+10.6%
11.7%US$1,300.00US$820.00n/a25
Sep ’25US$1,184.69
US$1,153.33
-2.6%
12.0%US$1,300.00US$805.00n/a25
Aug ’25US$1,093.14
US$1,119.01
+2.4%
12.9%US$1,300.00US$720.00n/a25
Jul ’25US$1,057.02
US$1,056.41
-0.06%
12.1%US$1,229.00US$720.00n/a25
Jun ’25US$980.16
US$1,047.65
+6.9%
11.7%US$1,185.00US$720.00n/a25
May ’25US$903.48
US$1,038.08
+14.9%
11.2%US$1,189.00US$720.00n/a25
Apr ’25US$969.31
US$1,022.19
+5.5%
11.3%US$1,184.00US$710.00n/a25
Mar ’25US$982.82
US$1,009.93
+2.8%
11.8%US$1,184.00US$710.00n/a23
Feb ’25US$957.78
US$968.35
+1.1%
11.8%US$1,125.00US$710.00n/a24
Jan ’25US$878.29
US$919.76
+4.7%
11.6%US$1,125.00US$700.00n/a24
Dec ’24US$814.86
US$908.57
+11.5%
10.7%US$1,066.00US$680.00n/a25
Nov ’24US$791.27
US$902.36
+14.0%
10.6%US$1,064.00US$680.00US$843.6023
Oct ’24US$822.96
US$898.87
+9.2%
10.5%US$1,050.00US$680.00US$1,046.9123
Sep ’24US$831.63
US$895.61
+7.7%
10.8%US$1,050.00US$665.00US$1,184.6923
Aug ’24US$739.07
US$857.78
+16.1%
10.6%US$1,045.00US$650.00US$1,093.1423
Jul ’24US$718.54
US$862.87
+20.1%
11.7%US$1,045.00US$650.00US$1,057.0223
Jun ’24US$731.17
US$883.78
+20.9%
10.9%US$1,050.00US$650.00US$980.1623
May ’24US$806.72
US$878.61
+8.9%
10.5%US$1,040.00US$650.00US$903.4823
Apr ’24US$821.67
US$871.83
+6.1%
10.9%US$1,040.00US$650.00US$969.3123
Mar ’24US$770.44
US$830.78
+7.8%
12.2%US$1,011.00US$605.00US$982.8223
Feb ’24US$758.00
US$806.78
+6.4%
12.5%US$1,023.00US$605.00US$957.7823
Jan ’24US$721.49
US$801.04
+11.0%
13.0%US$1,027.00US$595.00US$878.2923
Dec ’23US$761.24
US$795.83
+4.5%
13.3%US$1,027.00US$575.00US$814.8623
Nov ’23US$759.91
US$780.78
+2.7%
13.4%US$1,025.00US$575.00US$791.2723

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies